Form 4: Disc Medicine Director William White Executes Stock Sales Under 10b5-1 Plan
SEC Form 4 Filing
Director William Richard White of Disc Medicine, Inc. reports multiple transactions involving common stock and stock options, executed under a pre-arranged Rule 10b5-1 trading plan.
Summary
- William Richard White, a director at Disc Medicine, Inc., filed a Form 4 detailing changes in beneficial ownership.
- The reported transactions include the exercise of stock options and subsequent sale of common stock.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on December 13, 2023.
- On November 1, 2024, White exercised options to acquire 201 shares at $9.86 and sold them at an average price of $45.6804 and $46.7477.
- On November 4, 2024, White exercised options to acquire 7,136 shares at $45.69 and sold them at weighted average prices of $57.5914 and $58.9446.
- Following these transactions, White's direct ownership of common stock is reported as 0 shares.
- White still holds 2,005 stock options with an exercise price of $9.86 and 0 stock options with an exercise price of $45.69.
Sentiment
Score: 5
Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions by a company director under a pre-arranged trading plan. The reduction of direct holdings could be seen as slightly negative, but the 10b5-1 plan mitigates concerns about insider trading.
Positives
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.
Negatives
- The director has reduced their direct holdings of common stock to zero.
Risks
- Further sales by the director could exert downward pressure on the stock price.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. The use of a 10b5-1 plan is a common practice to allow insiders to sell shares without being accused of acting on non-public information.
Stakeholder Impact
- Shareholders may be interested in the trading activity of company insiders as an indicator of management's confidence in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 2021-09-01 | Shares underlying one option vest in 48 equal monthly installments following this date. |
| 2023-12-13 | Date the Rule 10b5-1 trading plan was adopted. |
| 2031-09-13 | Expiration date of one stock option. |
| 2033-06-08 | Expiration date of one stock option. |
| 2024-11-01 | Date of transactions involving the exercise of options and sale of 201 common shares. |
| 2024-11-04 | Date of transactions involving the exercise of options and sale of 7,136 common shares. |
| 2024-11-05 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.